Clinical Pharmacokinetics

, Volume 18, Issue 3, pp 220–239 | Cite as

Recent Developments in Hepatic Drug Oxidation Implications for Clinical Pharmacokinetics

  • Kim Brosen
Research Review


Cytochrome P450 (P450) is the collective term for a group of related enzymes or isozymes which are responsible for the oxidation of numerous drugs and other foreign compounds, as well as many endogenous substrates including prostaglandins, fatty acids and steroids. Each P450 is encoded by a separate gene, and a classification system for the P450 gene superfamily has recently been proposed. The P450 genes are assigned to families and subfamilies according to the degree of similarity of the amino acid sequences of the protein part of the encoded P450 isozymes. It is estimated that there are between 20 and 200 different P450 genes in humans.

The human P450IID6 is a particular isozyme which has been extensively studied over the past 10 years. The P450IID6 is the target of the sparteine/debrisoquine drug oxidation polymorphism. Between 5 and 10% of Caucasians are poor metabolisers, and it has recently been shown that the P450IID6 enzyme is absent in the livers of these individuals. The defect has also been characterised at the DNA and messenger RNA (mRNA) level, and to date 3 different forms of incorrectly spliced P450IID6 pre-mRNAs have been identified in the livers of poor metabolisers.

The P450IID6 has a broad substrate specificity and is known to oxidise 15 to 20 commonly used drugs. The metabolism of these drugs is therefore subjected to the sparteine/debrisoquine oxidation polymorphism. The clinical significance of this polymorphism for a particular drug is defined according to the usefulness of phenotyping patients before treatment. It is concluded that this strategy would be of potential value for tricyclic antidepressants, some neuroleptics (e.g. perphenazine and thioridazine) and some antiarrhythmics (e.g. propafenone and flecainide).

The P450IID6 displays markedly stereoselective metabolism and appears uninducible by common inducers like rifampicin and Phenazone (antipyrine). With some substrates, such as Imipramine, desipramine and propafenone. P450IID6 becomes saturated at therapeutic doses. Finally, its function is potently inhibited by many commonly used drugs, for example, quinidine.

The most clinically relevant interaction in relation to P450IID6 function appears to be the potent inhibition by some neuroleptics of the metabolism of tricyclic antidepressants.

No drug-metabolising P450 has been so well characterised at the gene, protein and functional levels as the P4501ID6. This development is based on an extensive use of specific model drugs, the oxidation of which in vitro and in vivo is dependent on the function of P450IID6; it can be expected that other human drug-metabolising P450s will be similarly characterised in future.


Imipramine Quinidine Desipramine Flecainide Poor Metabolisers 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alvan G. Grind M. Grafiner C,. Sjöqvisl F. Relationship of Ndemethylalion of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism. Clinical Pharmacology and Therapeutics 36: 515–519, 1984PubMedCrossRefGoogle Scholar
  2. Alvan G. von Bahr C Seideman P, Sjöqvisl F. High plasma concentrations of β-receplor blocking drugs and deficient debrisoquine hydroxylation. Lancet 1: 333. 1982PubMedCrossRefGoogle Scholar
  3. Balant-Gorgia AE. Balant LP. Genet C. Dayer P. Acschlimann JM. et al. Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites. European Journal of Clinical Pharmacology 31: 449–455. 1986PubMedCrossRefGoogle Scholar
  4. Balant-Gorgia AE. Schulz P. Dayer P, Balant L. Kübli A. et al. Role of oxidation polymorphism on blood and urine concentrations of amitriptyline and its metabolites in man. Archiv für Psychiatric und Nervenkrankheilen 232: 215–222. 1982CrossRefGoogle Scholar
  5. Balant LP, Gundcrt-Rcmy U, Boobis AR, von Bahr C. Genetic polymorphism in drug metabolism: relevance for the development of new drugs. European Journal of Clinical Pharmacology 36: 551–554, 1989PubMedCrossRefGoogle Scholar
  6. Bargetzi MJ, Aoyama T, Gonzalez FJ, Meyer UA. Lidocaine metabolism in human liver microsomes by cytochrome P450I11A4. Clinical Pharmacology and Therapeutics, in press. 1989Google Scholar
  7. Beckmann J. Hertrampf R, Gundert-Remy U. Mikus G, Gross AS. et al. Is there a genetic factor in flecainide toxicity? British Medical Journal 297: 1316. 1988PubMedCrossRefGoogle Scholar
  8. Bertilsson L. Aberg-Wistedt A. The debrisoquine hydroxylation lest predicts steady-state plasma levels of desipramine. British Journal of Clinical Pharmacology 15: 388–390, 1983PubMedCrossRefGoogle Scholar
  9. Bertilsson L. Eichelbaum M. Mellstrom B. Säwe J. Schulz H-V. et al. Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man. Life Sciences 27: 1673–1677. 1980PubMedCrossRefGoogle Scholar
  10. Bertilsson L. Henthorn TK, Sanch E, Tybring G, Säwe J. et al. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debriso-quin, hydroxylation phenotype. Clinical Pharmacology and Therapeutics 45: 348–355, 1989PubMedCrossRefGoogle Scholar
  11. Birgersson C, Morgan ET, Jörnvall H, von Bahr C. Purification of a desmethylimipraminc and debrisoquine hydroxylating cytochrome P-450 from human liver. Biochemical Pharmacology 35: 3165–3166. 1986PubMedCrossRefGoogle Scholar
  12. Boobis AR. Edwards RJ. Singleton A. Sesardic D, Murray B. et al. The contribution of polymorphic isozymes of cytochrome P-450 to pharmacokinetics and toxicity of foreign compounds in man. In Miners et al. (Eds) Microsomes and drug oxidations — proceedings of the VIIth International Symposium. Adelaide, Australia, pp. 216–223. Taylor & Francis, London, New York. Philadelphia. 1988Google Scholar
  13. Boobis AR, Murray S, Kahn GC. Robertz GM. Davies DS. Substrate specificity of the form of cytochrome P450 catalyzing the 4-hydroxylation of debrisoquine in man. Molecular Pharmacology 23: 474–481. 1983PubMedGoogle Scholar
  14. Brinn R. Brosen K, Gram LF. Haghfelt T. Otton SV. Sparteine oxidation is practically abolished in quinidine-treated patients. British Journal of Clinical Pharmacology 22: 194–197. 1986PubMedCrossRefGoogle Scholar
  15. Brosen K. The relationship between Imipramine metabolism and the sparteine oxidation polymorphism. (Thesis). Danish Medical Bulletin 35: 460–467, 1988PubMedGoogle Scholar
  16. Brosen K, Davidsen F. Gram LF. Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism. British Journal of Clinical Pharmacology, in press. 1989Google Scholar
  17. Brosen K, Gram LF. First-pass metabolism of Imipramine and desipramine: impact of the sparteine oxidation phenotype. Clinical Pharmacology and Therapeutics 43: 400–406. 1988PubMedCrossRefGoogle Scholar
  18. Brosen K. Gram LF. Quinidine potently inhibits the 2-hydrox-ylation of imipramine and desipramine but not the demethylalion of imipramine. European Journal of Clinical Pharmacology 37: 155–160, 1989aPubMedCrossRefGoogle Scholar
  19. Brosen K, Gram LF. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. European Journal of Pharmacology 36: 537–547, 1989bCrossRefGoogle Scholar
  20. Brosen K, Klysner R, Gram LF, Otton SV. Bech P, et al. Steadystate concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. European Journal of Clinical Pharmacology 30: 679–684. 1986bPubMedCrossRefGoogle Scholar
  21. Brosen K. Otton SV, Gram LF. Imipramine demcthylalion and hydroxylation: impact of the sparteine oxidation phenotype. Clinical Pharmacology and Therapeutics 40: 543–549. 1986aPubMedCrossRefGoogle Scholar
  22. Brosen K, Otton SV. Gram LF. Sparteine oxidation polymorphism, a family study. British Journal of Clinical Pharmacology 21: 661–667, 1986cPubMedCrossRefGoogle Scholar
  23. Cooper RG, Evans DAP. Price AH. Studies on the metabolism of perhexiline in man. European Journal of Clinical Pharmacology 32: 569–576. 1987PubMedCrossRefGoogle Scholar
  24. Dahl-Puustinen ML. Lidén A. Alm C. Nordin C, Bertilsson L. Disposition of perphenazine is related to the polymorphic debrisoquinc hvdroxylalion in human beings. Clinical Pharmacology and Therapeutics 46: 78–81. 1989PubMedCrossRefGoogle Scholar
  25. Dayer P. Desmeules J. Leemann T. Stribcrni R. Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hy-droxvlation. Biochemical and Biophysical Research Communications 152: 411–416. 1988PubMedCrossRefGoogle Scholar
  26. Dayer P. Gasser R. Gut J. Kronbach T. Robertz GM. et al. Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine/spaneine type polymorphism!. Biochemical and Biophysical Research Communications 125: 374–380. 1984PubMedCrossRefGoogle Scholar
  27. Dencker H. Dencker SJ. Green A. Nagy A. Intestinal absorption, demethylation and enterohepatic circulation of imipramine. Clinical Pharmacology and Therapeutics 19: 584–586. 1976PubMedGoogle Scholar
  28. Dcsmeules J. Dayer P. Gascon M-P. Magristis M. Impact of genetic and environmental factors in codeine analgesia. Clinical Pharmacology and Therapeutics 45: 122. 1989Google Scholar
  29. Distlerath LM. Reilly PEB. Martin MV. Davies GG. Wilkinson GR. et al. Purification and characterization of the human liver cytochrome P-450 involved in debrisoquine and phenacetin O-demethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. Journal of Biological Chemistry 260: 9057–9067. 1985PubMedGoogle Scholar
  30. Eichelbaum M. Baur MP. Dengler HJ. Osikowska-Evers BO. Tieves G. et al. Chromosomal assignment of human cytochrome P450 (debrisoquine/sparteinc type) to chromosome 22. British Journal of Clinical Pharmacology 23: 455–458. 1987PubMedCrossRefGoogle Scholar
  31. Eichelbaum M. Bertilsson L. Kupfer A. Steiner E. Meese CO. Enantioselectivity of 4-hydroxylation in extensive and poor metabolizers of debrisoquine. British Journal of Clinical Pharmacology 25: 505–508. 1988PubMedCrossRefGoogle Scholar
  32. Eichelbaum M. Bertilsson L. Sawe J. Zekorn C Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities. Clinical Pharmacology and Therapeutics 31: 184–186, 1982PubMedCrossRefGoogle Scholar
  33. Eichelbaum M. Mineshita S. Ohnhaus EE, Zekorn C. The influence of enzyme induction on polymorphic sparteine oxidation. British Journal of Clinical Pharmacology 22: 49–53. 1986PubMedCrossRefGoogle Scholar
  34. Eichelbaum M. Spannbrucker N. Dengler HJ. Influence of the defective metabolism of sparteine on its pharmacokinetics. European Journal of Clinical Pharmacology 16: 189–194. 1979bPubMedCrossRefGoogle Scholar
  35. Eichelbaum M. Spannbrucker N. Stemckc B. Dengler HJ. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. European Journal of Clinical Pharmacology 16: 183–187. 1979aPubMedCrossRefGoogle Scholar
  36. Evans DAP. Harmer D. Downham DV. Whibley EJ. Idle JR. et al. The genetic control of sparteine and debrisoquine metabolism with new methods of analysing biomodal distributions. Journal of Medical Genetics 20: 321–329, 1983PubMedCrossRefGoogle Scholar
  37. Evans DAP. Mahgoub A. Sloan TP. Idle JR. Smith RL. A family and population study of genetic polymorphism of debrisoquine oxidation in a white British population. Journal of Medical Genetics 17: 102–105. 1980PubMedCrossRefGoogle Scholar
  38. Feher MD. Lucas RA. Farid NA. Idle JR. Bergstrom RF. et al. Single dose pharmacokinetics of tomoxetine in poor and extensive melabolisers of debrisoquine. British Journal of Clinical Pharmacology 26: 231P. 1988Google Scholar
  39. Fonné-Pfister R. Meyer U.A. Xenobiolic and endobiotic inhibitors of cytochrome P450dbl function, the target of the debrisoquine/spaneine type polymorphism. Biochemical Pharmacology 37: 3829–3835. 1988PubMedCrossRefGoogle Scholar
  40. Freeman DJ. Martel R. Carruthers SG. Heinrichs D. Keown DA. et al. Cyclosporin-erythromycin interaction in normal subjects. British Journal of Clinical Pharmacology 23: 776–778. 1985Google Scholar
  41. Ged C. Umbenhauer DR. Bellew TM. Bork RW Srivastava PK. et al. Characterization of cDNAs. mRN As and proteins related to human liver microsomal cytochrome P-450 (S)-mephenytoin 4′-hydroxylalion. Biochemistry 27: 6929–6940. 1988PubMedCrossRefGoogle Scholar
  42. Gleiter CH. Aichele G. Nilsson E. Hengen N. Antonin KH. et al. Discovery of altered pharmacokinetics of CGP 15 210G in poor hydroxylators of debrisoquine during early drug development. British Journal of Clinical Pharmacology 20: 81–84. 1985PubMedCrossRefGoogle Scholar
  43. Gonzalez FJ. Skoda R. Kimura S. Umeno M. Zanger UM. et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature 331: 442–446. 1988aPubMedCrossRefGoogle Scholar
  44. Gonzalez FJ. Vilbois F. Hardwick JP. McBridge OW. Neben DW. et al. Human debrisoquine 4-hydroxylase (P450IIDI): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22. Genomics 2: 174–179. 1988bPubMedCrossRefGoogle Scholar
  45. Ciram LF. Brosen K. Inhibitors of the microsomal oxidation of psychotropic drugs: selectivity and clinical significance. In Dahl & Gram (Eds) Clinical pharmacology in psychiatry: from molecular studies to clinical reality, pp. 172–180. Springer Verlag, Heidelberg, 1989Google Scholar
  46. Gram LF. Brosen K. Kragh-Sorensen P. Chnstensen P. Steadystate levels of E- and Z-10-OH nortriptyline in nortriptyline treated patients: significance of concurrent mediation and the sparteine oxidation phenotvpe. Therapeutic Drug Monitoring 11: 508–514, 1989bPubMedCrossRefGoogle Scholar
  47. Gram LF, Christiansen J. First-pass metabolism of imipramine in man. Clinical Pharmacology and Therapeutics 17: 555–563. 1975PubMedGoogle Scholar
  48. Gram LF. Debruyne D. Caillard V. Boulenger J P. Lacotte J, et al. Substantial rise in sparteine metabolic ratio during halo-peridol treatment. British Journal of Clinical Pharmacology 27: 272–275. 1989aPubMedCrossRefGoogle Scholar
  49. Gram LF. Fredericson OK. Drug interaction: inhibitory effect of neuroleptics on the metabolism of tricyclic antidepressants in man. British Medical Journal 163: 463–465. 1972CrossRefGoogle Scholar
  50. Gram LF. Sondergaard I. Christiansen J. Petersen GO. Bech P. et al. Steady-state kinetics of imipramine in patients. Psychopharmacology 54: 255–261. 1977PubMedCrossRefGoogle Scholar
  51. Guengerich FP. Martin MV. Beaunc PH. Krcmers P. Wolff T. et al. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. Journal of Biological Chemistry 261: 5051–5060. 1986aPubMedGoogle Scholar
  52. Guengerich FP. Muller-Enoch D. Blair IA. Oxidation of quinidine by human liver cytochrome P-450. Molecular Pharmacology 30: 287–295. 1986bPubMedGoogle Scholar
  53. Ciut J. Catin T. Dayer P. Kronbach T. Zanger U, et al. Debrisoquine/sparteine-type polymorphism of drug oxidation. Journal of Biological Chemistry 261: 11734–11743. 1986bGoogle Scholar
  54. Gut J. Gasser R. Dayer P. Kronbach T. Catin T Debnsoquinetype polymorphism of drug oxidation: purification from human liver of a cytochrome P-450 isozyme with high activity for bufuralol hydroxylation. FEBS Letters 173: 287–290. 1984PubMedCrossRefGoogle Scholar
  55. Gut J. Meier UT. Catin T. Meyer U.A. Mephenytoin-type polymorphism of drug oxidation: purification and characterization of a human liver cytochrome P-450 isozyme catalyzing microsomal mephenytoin hvdroxvlation. Biochimica et Biophysica Acta 884: 435–447. 1986aPubMedCrossRefGoogle Scholar
  56. Inaba T. Jurima M. Mahon WA, Kalow W. In vitro studies of two isozymes of human liver cytochrome P450 Mephenytoin p-hydroxylase and sparteine monooxygenase. Drug Metabolism and Disposition 13: 443–448. 1985PubMedGoogle Scholar
  57. Lyun AO. Lennard MS. Tucker GT. Woods HF. Metroprolol and debnsoquin metabolism in Nigerians: lack of evidence for polymorphic oxidation. Clinical Pharmacology and Therapeutics 40: 387–394. 1986CrossRefGoogle Scholar
  58. Jackson PR. Tucker GT. Lennard S. Woods HF. Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices. British Journal of Clinical Pharmacology 22: 541–550. 1986PubMedCrossRefGoogle Scholar
  59. Kitchen I. Tremblay J. Audré J. Dring LG. Idle JR. et al. Inter-individual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamine. Xenobiotica 9: 397–404. 1979PubMedCrossRefGoogle Scholar
  60. Knodell RG. Raghvcndra KD. Wilkinson GR. Guengerich FP. Oxidative metabolism of hexobarbital in human liver: relationship to polymorphic S-mephenytoin 4-hydroxylation. Journal of Pharmacology and Experimental Therapeutics 245: 845–849. 1988PubMedGoogle Scholar
  61. Kroemer HK. Mikus G. Kronbach T. Meyer UA. Eichelbaum M. In vitro characterisation of the human cytochrome P-450 involved in polymorphic oxidation of propafenone. Clinical Pharmacology and Therapeutics 45: 28–33. 1989PubMedCrossRefGoogle Scholar
  62. Kronbach T. Fischer V. Meyer UA. Cyclosporine metabolism in human liver: identification of a cytochrome P450III gene family as the major cyclosporine metabolizing enzyme explains interactions of cyclosporine with other drugs. Clinical Pharmacology and Therapeutics 43: 630–635. 1988PubMedCrossRefGoogle Scholar
  63. Kronbach T. Mathys D. Gut J. Catin T. Meyer UA. High-performance liquid chromatographic assays for bufuralol I’-hydroxylase, debrisoquinc 4-hydroxylase, and dextromethorphan O-demelhylasc in microsomes and purified cytochrome P-450 isozymes of human liver. Analytical Biochemistry 162: 24–32. 1987PubMedCrossRefGoogle Scholar
  64. Kronbach T. Mathys D. Umeno M. Gonzalez FJ. Meyer UA. Oxidation of midazolam and triazolam by human liver cytochrome P450111A4. Molecular Pharmacology 36: 89–96. 1989PubMedGoogle Scholar
  65. Kupfer A. Branch RA. Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation. Clinical Pharmacology and Therapeutics 38: 414–418. 1985PubMedCrossRefGoogle Scholar
  66. Kupfer A. Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. European Journal of Clinical Pharmacology 26: 753–759. 1984PubMedCrossRefGoogle Scholar
  67. Leemann TP. Dayer P. Meyer UA. Single-dose quinidinc treatment inhibits meloprolol oxidation in extensive metabolisers. European Journal of Clinical Pharmacology 29: 739–741, 1986PubMedCrossRefGoogle Scholar
  68. Lennard MS. Tucker GT. Silas JH. Freestone S. Ramsay LE. et al. Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers. Clinical Pharmacology and Therapeutics 34: 732–737. 1983PubMedCrossRefGoogle Scholar
  69. Lewis RV. Lennard MS. Jackson PR. Tucker GT. Ramsay LE. et al. Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics. British Journal of Clinical Pharmacology 19: 329–333. 1985PubMedCrossRefGoogle Scholar
  70. Lou YC, Ying L, Bertilsson L, Sjöqvist F. Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet 2: 852–853. 1987PubMedGoogle Scholar
  71. Mackiewich R. Martin JB. Pain: pathophysiology and management. In Braunwald et al. (Eds) Harrison’s principles of internal medicine, 11th ed. pp. 13–17. McGraw Hill. 1987Google Scholar
  72. Mahgoub A, Idle JR. Dring LG. Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. Lancet 2: 584–586. 1977PubMedCrossRefGoogle Scholar
  73. McGourty JC. Silas JH. Lennard MS, Tucker GT. Woods HF. Metoprolol metabolism and debrisoquine oxidation polymorphism — population and family studies. British Journal of Clinical Pharmacology 20: 555–566. 1985PubMedCrossRefGoogle Scholar
  74. Meier PJ. Mueller HK, Dick B. Meyer UA. Hepatic monooxy-genase activities in subjects with a genetic defect in drug oxidation. Gastroenterology 85: 682–692. 1983PubMedGoogle Scholar
  75. Mellslröm B. Bertilsson L, Lou Y-C, Sawe J, Sjöqvist F. Amitriptyline metabolism: relationship to polymorphic debrisoquine hydroxylation. Clinical Pharmacology and Therapeutics 34: 516–520. 1983CrossRefGoogle Scholar
  76. Mellslröm B, Bertilsson L. Säwe J. Schulz H-V. Sjöqvist F. E-and Z-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clinical Pharmacology and Therapeutics 30: 189–193. 1981CrossRefGoogle Scholar
  77. Meyer UA, Gut J, Kronbach T. Skoda C. Meier UT. et al. The molecular mechanisms of two common polymorphisms of drug oxidation — evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation. Xenobiotica 16: 449–464. 1986PubMedCrossRefGoogle Scholar
  78. Mikus G, Ha HR. Vozeh S, Zekorn F. Follath F, et al. Pharmacokinetics and metabolism of quinidine in extensive and poor metabolizers of sparteine. European Journal of Clinical Pharmacology 31: 69–72. 1986PubMedCrossRefGoogle Scholar
  79. Nakamura K. Goto F. Ray WA. McAllister CB. Jacqc E. et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clinical Pharmacology and Therapeutics 38: 402–408. 1985PubMedCrossRefGoogle Scholar
  80. Neben DW. Adesnick M. Coon MJ. Estabrook RW, Gonzalez FJ, el al. The P450 gene superfamily: recommended nomenclature. DNA 6: 1–11, 1987CrossRefGoogle Scholar
  81. Neben DW, Nelson DR. Adesnik M. Coon MJ. Estabrook RW. et al. The P450 superfamily: update on listing of all genes and recommended nomenclature of the chomosomal loci. DNA 8: 1–13. 1989CrossRefGoogle Scholar
  82. Nelson DR. Strobel HW, Evolution of P450 proteins. Molecular Biology of Evolution 4: 572–593. 1987Google Scholar
  83. Oates NS. Shah RR. Idle JR. Smith RC. Influence of oxidation polymorphism on phenformin kinetics and dynamics. Clinical Pharmacology and Therapeutics 34: 827–834, 1983PubMedCrossRefGoogle Scholar
  84. Otton SV, Brinn RV, Gram LF. In vitro evidence against the oxidation of quinidine by the spaneine/debrisoquine monox-ygenase of the human liver. Drug Metabolism and Disposition 16: 15–17. 1988aPubMedGoogle Scholar
  85. Otton SV, Crewe HK, Lennard MS, Tucker GT, Woods HF. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics 247: 242–247, 1988bPubMedGoogle Scholar
  86. Otton SV, Inaba T, Kalow W. Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs. Life Sciences 34: 73–80, 1984PubMedCrossRefGoogle Scholar
  87. Otton SV, Inaba T, Mahon WA, Kalow W. In vitro metabolism of sparteine by human liver, competitive inhibition by debrisoquine. Canadian Journal of Physiology and Pharmacology 60: 102–105. 1982PubMedCrossRefGoogle Scholar
  88. Pierce MD, Smith SE, Franklin RA. The pharmacokinetics of Indoramin and 6-hydroxyindoram in poor and extensive metabolizers of debrisoquine. European Journal of Clinical Pharmacology 33: 59–65. 1987PubMedCrossRefGoogle Scholar
  89. Rollins DE. Alvan G. Bertilsson L. Gillette JR. Mellslröm B. et al. Interindividual differences in amitriptyline demethylation. Clinical Pharmacology and Therapeutics 28: 121–129, 1980PubMedCrossRefGoogle Scholar
  90. Rowland M, Tozer TN. Clinical pharmacokinetics — concepts and applications. Lea and Febiger, Philadelphia, 1980Google Scholar
  91. Roy SD. Hawes EM. McKay G. Korchinski ED, Midha KK. Metabolism of methoxyphenamine in extensive and poor metabolizers of debrisoquin. Clinical Pharmacology and Therapeutics 38: 128–133, 1985PubMedCrossRefGoogle Scholar
  92. Schellens JHM. Characterization of a human drug oxidation in vivo — development of a ‘Cocktail’ study design. Thesis, University of Leiden, The Netherlands, 1988Google Scholar
  93. Sesardic D, Boobis AR, Edwards RJ. Davies DS. A form of cytochrome P450 in man, orthologous to form d in the rat, catalyzes the O-dcethy lation of phenacetin and is inducible by cigarette smoking. British Journal of Clinical Pharmacology 26: 363–372, 1988PubMedCrossRefGoogle Scholar
  94. Shimada T, Misono KS. Guengerich FP. Human liver microsomal cytochrome P-450 mephenytoin 4-hyroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Journal of Biological Chemistry 261: 909–921. 1986PubMedGoogle Scholar
  95. Siddoway LA, Thompson KA, McAllister CB. Wang T, Wilkinson GR. et al. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 75: 785–791. 1987PubMedCrossRefGoogle Scholar
  96. Sloan TP, Lancaster R, Shah RR, Idle JR. Smith RL. Genetically determined oxidation capacity and the disposition of debrisoquine. British Journal of Clinical Pharmacology 15: 443–450. 1983PubMedCrossRefGoogle Scholar
  97. Sloan TP. Mahgoub A. Lancaster R. Idle JR. Smith RL. Polymorphism of carbon oxidation of drugs and clinical implications. British Medical Journal 2: 655–657. 1978PubMedCrossRefGoogle Scholar
  98. Speight TM (Ed.) Avery’s drug treatment: principles and practice of clinical pharmacology and therapeutics. 3rd ed.. ADIS Press Limited, Auckland. 1987Google Scholar
  99. Speirs CJ. Murray S. Boobis AR. Seddon CE. Davies DS. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debnsoquine. British Journal of Clinical Pharmacologv 22: 739–743. 1986CrossRefGoogle Scholar
  100. Steiner E, Bertilsson L. Sawe J. Berthling I. Sjoqvisl F. Polymorphic debnsoquin hydroxylation in 757 Swedish subjects. Clinical Pharmacology and Therapeutics 44: 431–435. 1988aPubMedCrossRefGoogle Scholar
  101. Steiner E. Dumont E. Spina E. Dahlqvist R. Inhibition of desipramine 2-hydroxylation by quinidine and quinine. Clinical Pharmacology and Therapeutics 43: 577–581. 1988bPubMedCrossRefGoogle Scholar
  102. Steiner E. Iselius L. Alvan G. Lindsten J. Sjoqvist F. A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin. Clinical Pharmacology and Therapeutics 38: 394–401, 1985PubMedCrossRefGoogle Scholar
  103. Tsuchiya T. Levy V. Relationship between dose and plateau levels of drugs eliminated by parallel first order and capacity limited kinetics. Journal of Pharmaceutical Science 61: 541–544. 1972CrossRefGoogle Scholar
  104. Vogel F. Motulsky AG. Human genetics, problems and approaches. Springer-Verlag, Berlin, Heidelberg, New York, 1982Google Scholar
  105. von Bahr C, Birgersson C, Blanck A. Göransson M, Mellstrom B, et al. Correlation between nortriptyline and debrisoquine hvdroxvlation in the human liver. Life Sciences 33: 631–636. 1983CrossRefGoogle Scholar
  106. von Bahr C. Groth CG. Jansson H. Lundgren G, Lind M. et al. Drug metabolism in vitro: establishment of a human liver bank. Clinical Pharmacology and Therapeutics 27: 711–725, 1980CrossRefGoogle Scholar
  107. von Bahr C. Guengerich FP. Movin G, Nordin C The use of human liver banks in pharmacogenelic research. In Dahl & Gram (Eds) Clinical pharmacology in psychiatry: from molecular studies to clinical reality, pp. 163–171, Springer Verlag, Heidelberg, 1989CrossRefGoogle Scholar
  108. von Bahr C, Spina E, Birgersson C,, Ericsson Ö, Göransson M, et al. Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. Biochemical Pharmacology 34: 2501–2505. 1985CrossRefGoogle Scholar
  109. Wagner F. Tlenk D. Jänchen E, Roskamm H, Kalusche D Drug interaction between propafenone and metoprolol. British Journal of Clinical Pharmacology 24: 213–220. 1987PubMedCrossRefGoogle Scholar
  110. Watkins PB. Wrightson SA. Muriel P. Schuelz EG. Mendez-Picon G, et al. Identification of an inducible form of cytochrome P-450 in human liver. Proceedings of the National Academy of Sciences 82: 6310–6314. 1985CrossRefGoogle Scholar
  111. Wolf T. Distlerath LM, Worthington MT. Groopman JD. Hammons GT, et al. Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modelling. Cancer Research 45: 2116–2122. 1985Google Scholar
  112. Zanger UM, Hauri HP, Loeper J, Homberg JC, Meyer UA. Antibodies against human cytochrome P450dbl in autoimmune hepatitis type II Proceedings of the National Academy of Sciences 85: 8256–8260. 1988bGoogle Scholar
  113. Zanger LIM, Vilbois F, Hardwick J, Meyer UA. Absence of hepatic cytochrome P450buflcauses genetically deficient debrisoquine oxidation in man. Biochemistry 27: 5447–5454. 1988aPubMedCrossRefGoogle Scholar
  114. Zekorn C, Achten G, Hausleiter HJ. Moon CH. Eichelbaum M. Pharmacokinetics of N-propylajmaline in relation to polymorphic sparteine oxidation. Klinische Wochenschrift 63: 1180–1186, 1985PubMedCrossRefGoogle Scholar

Copyright information

© ADIS Press Limited 1990

Authors and Affiliations

  • Kim Brosen
    • 1
    • 2
  1. 1.Department of Clinical PharmacologyOdense UniversityOdense CDenmark
  2. 2.Department of PharmacologyBiocenter of the UniversityBaselSwitzerland

Personalised recommendations